CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.

IF 33.7 1区 医学 Q1 Medicine Mmwr Recommendations and Reports Pub Date : 2024-06-06 DOI:10.15585/mmwr.rr7302a1
Laura H Bachmann, Lindley A Barbee, Philip Chan, Hilary Reno, Kimberly A Workowski, Karen Hoover, Jonathan Mermin, Leandro Mena
{"title":"CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.","authors":"Laura H Bachmann, Lindley A Barbee, Philip Chan, Hilary Reno, Kimberly A Workowski, Karen Hoover, Jonathan Mermin, Leandro Mena","doi":"10.15585/mmwr.rr7302a1","DOIUrl":null,"url":null,"abstract":"<p><p>No vaccines and few chemoprophylaxis options exist for the prevention of bacterial sexually transmitted infections (STIs) (specifically syphilis, chlamydia, and gonorrhea). These infections have increased in the United States and disproportionately affect gay, bisexual, and other men who have sex with men (MSM) and transgender women (TGW). In three large randomized controlled trials, 200 mg of doxycycline taken within 72 hours after sex has been shown to reduce syphilis and chlamydia infections by >70% and gonococcal infections by approximately 50%. This report outlines CDC's recommendation for the use of doxycycline postexposure prophylaxis (doxy PEP), a novel, ongoing, patient-managed biomedical STI prevention strategy for a selected population. CDC recommends that MSM and TGW who have had a bacterial STI (specifically syphilis, chlamydia, or gonorrhea) diagnosed in the past 12 months should receive counseling that doxy PEP can be used as postexposure prophylaxis to prevent these infections. Following shared decision-making with their provider, CDC recommends that providers offer persons in this group a prescription for doxy PEP to be self-administered within 72 hours after having oral, vaginal, or anal sex. The recommended dose of doxy PEP is 200 mg and should not exceed a maximum dose of 200 mg every 24 hours.Doxy PEP, when offered, should be implemented in the context of a comprehensive sexual health approach, including risk reduction counseling, STI screening and treatment, recommended vaccination and linkage to HIV PrEP, HIV care, or other services as appropriate. Persons who are prescribed doxy PEP should undergo bacterial STI testing at anatomic sites of exposure at baseline and every 3-6 months thereafter. Ongoing need for doxy PEP should be assessed every 3-6 months as well. HIV screening should be performed for HIV-negative MSM and TGW according to current recommendations.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"73 2","pages":"1-8"},"PeriodicalIF":33.7000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7302a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

No vaccines and few chemoprophylaxis options exist for the prevention of bacterial sexually transmitted infections (STIs) (specifically syphilis, chlamydia, and gonorrhea). These infections have increased in the United States and disproportionately affect gay, bisexual, and other men who have sex with men (MSM) and transgender women (TGW). In three large randomized controlled trials, 200 mg of doxycycline taken within 72 hours after sex has been shown to reduce syphilis and chlamydia infections by >70% and gonococcal infections by approximately 50%. This report outlines CDC's recommendation for the use of doxycycline postexposure prophylaxis (doxy PEP), a novel, ongoing, patient-managed biomedical STI prevention strategy for a selected population. CDC recommends that MSM and TGW who have had a bacterial STI (specifically syphilis, chlamydia, or gonorrhea) diagnosed in the past 12 months should receive counseling that doxy PEP can be used as postexposure prophylaxis to prevent these infections. Following shared decision-making with their provider, CDC recommends that providers offer persons in this group a prescription for doxy PEP to be self-administered within 72 hours after having oral, vaginal, or anal sex. The recommended dose of doxy PEP is 200 mg and should not exceed a maximum dose of 200 mg every 24 hours.Doxy PEP, when offered, should be implemented in the context of a comprehensive sexual health approach, including risk reduction counseling, STI screening and treatment, recommended vaccination and linkage to HIV PrEP, HIV care, or other services as appropriate. Persons who are prescribed doxy PEP should undergo bacterial STI testing at anatomic sites of exposure at baseline and every 3-6 months thereafter. Ongoing need for doxy PEP should be assessed every 3-6 months as well. HIV screening should be performed for HIV-negative MSM and TGW according to current recommendations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国疾病预防控制中心关于使用强力霉素暴露后预防措施预防细菌性传播感染的临床指南,2024 年。
在预防细菌性性传播感染 (STI)(特别是梅毒、衣原体和淋病)方面,目前还没有疫苗和化学预防方案。这些感染在美国呈上升趋势,对男同性恋、双性恋和其他男男性行为者(MSM)以及变性女性(TGW)的影响尤为严重。在三项大型随机对照试验中,性生活后 72 小时内服用 200 毫克强力霉素可使梅毒和衣原体感染率降低 70%以上,淋球菌感染率降低约 50%。本报告概述了疾病预防控制中心关于使用强力霉素暴露后预防(doxy PEP)的建议,这是一种针对特定人群的新型、持续性、由患者管理的生物医学性传播感染预防策略。疾控中心建议,在过去 12 个月内确诊过细菌性 STI(特别是梅毒、衣原体或淋病)的 MSM 和 TGW 应接受咨询,了解强力霉素暴露后预防疗法可用于预防这些感染。在与医疗服务提供者共同做出决定后,疾病预防控制中心建议医疗服务提供者为这类人群提供强力PEP处方,让他们在口交、阴道性交或肛交后72小时内自行服用。多西 PEP 的推荐剂量为 200 毫克,每 24 小时的最大剂量不应超过 200 毫克。提供多西 PEP 时,应在综合性健康方法的背景下实施,包括降低风险咨询、性传播感染筛查和治疗、推荐疫苗接种以及与 HIV PrEP、HIV 护理或其他适当服务的联系。接受强力PEP治疗的人应在基线时和之后每3-6个月在暴露的解剖部位接受细菌性传播感染检测。此外,还应每隔 3-6 个月评估一次对强力 PEP 的持续需求。应根据现行建议,对 HIV 阴性的 MSM 和 TGW 进行 HIV 筛查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
期刊最新文献
CDC Program Evaluation Framework, 2024. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1